Enanta制药宣布新的研发活动在乙型肝炎病毒和呼吸道合胞病

StephenW

Enanta Pharmaceuticals Announces New R&D Initiatives in Hepatitis B Virus and Respiratory Syncytial Virus and Plan to Provide Data Updates on Programs in NASH and HCV at the 34th Annual J.P. Morgan Healthcare Conference

    Updates on Enanta’s wholly-owned programs to be presented on Wednesday, January 13 at 11:00 a.m. PT at the 34th Annual J.P. Morgan Healthcare Conference
    First subject dosed in phase 1 clinical study with cyclophilin inhibitor EDP-494 for hepatitis C virus infection

January 11, 2016 08:00 AM Eastern Standard Time

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced today that it has expanded its research and development programs within the company’s core focus areas of virology and liver disease to include new programs to treat hepatitis B virus (HBV) and respiratory syncytial virus (RSV) infections. Enanta also announced that the first subject was dosed in a phase 1 clinical study with EDP-494, its cyclophilin inhibitor for the treatment of hepatitis C virus (HCV).

    “Our successful HCV collaboration, our drug discovery expertise and our experience in virology resulted in our first marketed product with AbbVie, paritaprevir, which is part of the VIEKIRA PAK® combination HCV therapy”
    Tweet this

Enanta has ongoing internal research and development in four disease areas: HCV, HBV, RSV, and non-alcoholic steatohepatitis (NASH). Updates on all four wholly-owned programs will be presented on Wednesday, January 13 at 11:00 a.m. PT at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco.

“Our successful HCV collaboration, our drug discovery expertise and our experience in virology resulted in our first marketed product with AbbVie, paritaprevir, which is part of the VIEKIRA PAK® combination HCV therapy,” commented Jay R. Luly, Ph.D. President and Chief Executive Officer. “We are now in a position to diversify and grow beyond HCV and to expand our research into other areas where we can develop new therapies for patients with limited treatment options.”

New Programs in Respiratory Syncytial Virus (RSV) and Hepatitis B Virus (HBV)

Building on Enanta’s knowledge and experience in developing treatments for virological diseases such as HCV, Enanta has initiated programs in two new areas where there is a large opportunity and an unmet medical need; RSV and HBV.

RSV is a viral lung infection that is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States. Each year, 75,000 to 125,000 children in this age group are hospitalized due to RSV infection.1 RSV also causes serious complications in immune-compromised populations and the elderly.2 There are currently no safe and effective treatments available.

HBV is a potentially life-threatening liver infection. It is estimated that 15-25% of patients with chronic HBV infection will develop chronic liver diseases including cirrhosis, hepatocellular carcinoma, or liver decompensation, with more than 780,000 deaths every year due to these complications.3

Significant progress has been made in discovering, characterizing, and seeking patent protection for new core inhibitors for HBV and new non-fusion inhibitors for RSV. Enanta expects to initiate phase 1 clinical development in at least one of the new programs in 2017.

StephenW

Enanta制药宣布新的研发活动在乙型肝炎病毒和呼吸道合胞病毒，并计划在第34届摩根大通保健大会提供的程序在NASH数据更新和HCV

    在Enanta的全资程序的更新，以在第34届摩根大通保健大会提交上周三，1月13日上午11:00 PT
    加料，第一阶段的临床研究，亲环素抑制剂EDP-494为丙型肝炎病毒感染的第一个主题

2016年1月11日08:00 AM东部标准时间

水城，大众 - （BUSINESS WIRE） - Enanta制药公司（纳斯达克股票代码：ENTA），一家以研发为重点的生物技术公司，致力于创造小分子药物对病毒感染和肝脏疾病，今天宣布，它已扩大其研发公司的核心焦点病毒学和肝脏疾病领域内的计划，包括新的方案来治疗乙型肝炎病毒（HBV）和呼吸道合胞病毒（RSV）感染。 Enanta还宣布，第一个主题是给予在第一阶段的临床研究，EDP-494，其亲环蛋白抑制剂丙型肝炎病毒（HCV）的治疗。

    “我们成功的HCV协作，我们的药物发现的专门知识以及我们在病毒学经验导致我们的第一个市售产品与艾伯维，paritaprevir，这是VIEKIRAPAK®组合HCV治疗的一部分”
    到Twitter

Enanta有持续的内部研究和发展的四个疾病领域：丙型肝炎病毒，乙肝病毒，呼吸道合胞病毒，和非酒精性脂肪性肝炎（NASH）。在所有四家全资程序的更新将出现在周三，1月13日上午11:00 PT在第34届摩根大通保健在旧金山会议。

“我们的成功HCV的合作，我们的药物发现的专业知识和我们的病毒学的经验导致了我们的第一个上市的产品与艾伯维，paritaprevir，这是VIEKIRAPAK®合并HCV治疗的一部分，”评论杰伊R. Luly博士总裁兼首席执行官。 “我们现在在一个位置，多样化和增长超过HCV和扩大我们的研究到其他领域，我们可以开发新疗法的患者有限的治疗选择。”

在呼吸道合胞病毒（RSV）和乙肝病毒的新程序（HBV）

建立在Enanta的知识和在制定病毒学疾病如丙型肝炎的治疗经验，Enanta已开始计划在两个新的地方有一个大的机会，未满足的医疗需求;呼吸道合胞病毒和乙肝病毒。

RSV是一种病毒性肺部感染是支气管炎在美国最常见的原因（小气道的炎症在肺中）和肺炎的儿童1岁的年龄。每年75,000 125,000孩子在这个年龄组住院，由于RSV infection.1 ​​RSV也会引起严重的并发症，免疫功能低下的人群和elderly.2目前尚无安全有效的治疗方法可用。

乙肝是一种潜在威胁生命的肝脏感染。据估计，慢性HBV感染的15-25％，每年将发展为慢性肝病，包括肝硬化，肝癌或肝功能失代偿，有78万多人死于这些complications.3

显著的进步已取得发现，表征，并寻求专利保护的新的核心抑制剂HBV和新的非融合抑制剂用于呼吸道合胞病毒。 Enanta预计以引发第一阶段的临床发展中的新的方案中的至少一个在2017年。